fda-approved
(3)
Michael Bigham
Michael F. Bigham is a veteran biopharmaceutical executive and investor who spent nearly a decade as Chairman and CEO of Paratek Pharmaceuticals, guiding the company through the FDA approval and commercial launch of NUZYRA (omadacycline) - a novel tetracycline-class antibiotic tackling drug-resistant bacterial infections. A Stanford MBA and CPA with roots in Gilead Sciences' early days, he has built, funded, and led companies across the full arc of drug development. He now operates as founder and managing director of Firebrand River Capital.
Rick Winningham
Rick Winningham is the CEO of Theravance Biopharma, a biopharmaceutical company focused on organ-selective medicines for serious diseases including COPD, rare neurological conditions, and inflammatory diseases. With over 40 years in the pharmaceutical industry - including 13 years as CEO of Innoviva and 15 years at Bristol-Myers Squibb - Winningham has built a career defined by transformative drug development, strategic company leadership, and a widely recognized commitment to mentoring the next generation of biopharma executives, particularly women in leadership. He was named the 2026 HBA Honorable Mentor by the Healthcare Businesswomen's Association.
Valeska Schroeder
Valeska Schroeder, Ph.D., is CEO and Chairman of the Board at Cerapedics Inc., the Colorado-based orthobiologics company behind i-FACTOR and PearlMatrix - two of only three FDA PMA-approved bone grafts on the U.S. spine market. A materials scientist by training (BS, MS, PhD from UC Berkeley), she spent the first part of her career in medtech product development before transitioning to venture investing at KCK MedTech, where she led deals and sat on boards of companies including Sight Sciences, Aerin Medical, Intuity Medical, and Lungpacer. She joined Cerapedics' board in 2018, deepened her involvement in 2021, and took the helm as CEO in November 2022, steering the company through PearlMatrix's landmark FDA approval in June 2025 - making Cerapedics the only company with two PMA-approved spinal biologics.